Neoadjuvant and Adjuvant Treatment of HER2-Positive Breast Cancer

Podcast

Dr Kaklamani and colleagues take an in-depth look at data from select clinical trials in the neoadjuvant and adjuvant settings for patients with HER2-positive breast cancer.

Related Videos
Shruti Tiwari, MD
Video 5 - "AE Management with CDK4/6 Inhibitors: Strategies for Treatment Continuity and Optimal Patient Outcomes"
Rita Nanda, MD
Siddartha Yadav, MD, FACP
Shruti Tiwari, MD
Nan Chen, MD
Julia Foldi, MD, PhD
Video 4 - "The Evolving Treatment Landscape with CDK4/6 Inhibitors in Early HR+/HER2- Breast Cancer"
Margaret E. Gatti-Mays, MD, MPH, FACP, of The Ohio State University Comprehensive Cancer Center
Ko Un “Clara” Park, MD
Related Content
Robert W. Mutter, MD

Data Continue to Illustrate Potential Role of Partial Breast Irradiation in Early-Stage Breast Cancer

April 24th 2024
Article
Andrew J. Wagner, MD, PhD, medical director, Ambulatory Oncology, senior physician, Dana-Faber Cancer Institute; associate professor, medicine, Harvard Medical School

Wagner on the Investigation of Nab-Sirolimus in Advanced Malignant PEComa

March 28th 2024
Podcast
FDA

FDA Approves Lumisight and Lumicell DVS for Residual Breast Cancer Detection

April 18th 2024
Article
Stephen Bagley, MD, MSCE, assistant professor, medicine, hematology-oncology, the Hospital of the University of Pennsylvania; section chief, Neuro-Oncology, assistant professor, medicine, neurosurgery, Penn Medicine

Bagley Summarizes the ACTION trial of ONC201 in H3 K27M–Mutant Diffuse Midline Gliomas

March 21st 2024
Podcast
Anne Favret, MD

Examining the Evolution of Treatment With CDK4/6 Inhibitors in Metastatic Breast Cancer

April 12th 2024
Article
Matt Coffey, PhD, president, chief executive officer, Oncolytics Biotech

FDA Receives Type C Meeting Request for Pelareorep in HR+/HER2– Metastatic Breast Cancer

April 12th 2024
Article